Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Washington State Sues OxyContin Maker Purdue Pharma

Nate Raymond  |  September 29, 2017

(Reuters)—Washington state on Thursday sued OxyContin maker Purdue Pharma LP, becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for a national opioid addiction epidemic. The city of Seattle also filed a separate lawsuit against Purdue as well as units of Teva Pharmaceutical Industries Ltd, Johnson and…

Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA

Michael Erman  |  September 29, 2017

NEW YORK (Reuters)—Makers of fast-acting opioids will have to fund voluntary training for healthcare professionals who prescribe the drugs, including education on safe prescribing practices and non-opioid alternatives, the course  said on Thursday. The FDA sent letters to 74 manufacturers of immediate-release opioids, notifying them that they will have to fund the development of courses…

Help Pediatric Patients Overcome Pain & Anxiety

Karen Appold  |  September 29, 2017

Pediatric rheumatology patients present unique challenges. According to Kyla Driest, MD, MEd, using age and temperament appropriate methods, such as distraction or icing, may help children manage pain and ease anxiety…

As 2018 Obamacare Deadline Nears, U.S. States Believe Every County Covered

Caroline Humer  |  September 27, 2017

NEW YORK (Reuters)—U.S. states have negotiated to the bitter end to keep health insurers selling Obamacare plans in every county next year, in some cases taking a hard-line to prevent exits that leave residents without access to health coverage. But states cannot rule out a last-minute pullout by an insurance company. Insurers must sign government…

From the Front Lines: Managing RA Comorbidities in Primary Care

Arthritis Care & Research  |  September 27, 2017

How are comorbidities for RA patients managed outside of rheumatology? A recent Canadian study developed and assessed quality measures related to preventive care and screenings for RA patients in a primary care setting, comparing RA and non-RA patients. The results: Primary care physicians often provide similar levels of care to patients with and without RA. But RA patients were less likely to receive some cancer screenings and all necessary tests to assess their cardiovascular risk…

Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

Michele B. Kaufman, PharmD, BCGP  |  September 27, 2017

Patients who receive abaloparatide and switch to alendronate have a statistically significant reduction in fracture risk through 3.5 years, according to a new study…

Insights into Precision Immunology for Research, RA & Infection

Lara C. Pullen, PhD  |  September 26, 2017

Research in precision immunology is in its early stages. But new insights into cohorts, RA gene expression and infection presented at FOCUS 2017 may benefit future research and patient care…

A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome

Lara C. Pullen, PhD  |  September 26, 2017

A session at the FOCIS 2017 meeting examined the current challenges and understanding of chronic fatigue syndrome, also called myalgic encephalomyelitis, in the hope of stimulating new approaches to deciphering the disease’s mechanistic and immunological underpinnings…

AMP RA/Lupus Network Shares Its Progress

Lara C. Pullen, PhD  |  September 26, 2017

Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…

Republican Bill to Repeal Obamacare Teeters on Edge of Collapse

Susan Cornwell & Richard Cowan  |  September 25, 2017

WASHINGTON (Reuters)—The latest Republican effort to repeal former U.S. President Barack Obama’s signature healthcare law faced possible defeat this week as several senators in the party voiced concerns about the bill under consideration. The U.S. Senate is up against a Saturday deadline for deciding the fate of the 2010 Affordable Care Act, popularly known as…

  • « Previous Page
  • 1
  • …
  • 397
  • 398
  • 399
  • 400
  • 401
  • …
  • 818
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences